

June 2024

NEW ONCOLOGY GENETIC TESTING FOR SOLID TUMOURS

We are excited to announce the launch of the latest addition to our solid tumour genetic testing repertoire, **the Oncomine™ Comprehensive Assay Plus (OCAPLUS)**.

The OCAPLUS assay is performed using Ion Torrent Next Generation Sequencing (NGS) technology and allows for some of the most comprehensive tumour genomic profiling currently available in South Africa. This assay includes:

- **Comprehensive tumour profiling – 500 key cancer genes sequenced**
- **Tumour mutational burden (TMB) testing**
- **Microsatellite instability (MSI) testing**
- **Homologous recombination deficiency (HRD) testing**

The OCAPLUS allows for the simultaneous detection of targetable variants across an extensive range of solid tumours, making it a more cost-effective approach than testing for all the individual components listed above. TMB can also be requested as a stand-alone test.

The table below summarises this new and other molecular testing offered for solid tumours at Ampath with key differences highlighted:

	Oncomine™ Comprehensive Assay Plus	Oncomine™ Precision Assay	DNA-only NGS
Number of cancer genes covered	~500 (including 49 fusion genes)	~50 (including 18 fusion genes)	~50
Fusions detectable	✓	✓	X
Copy number variants detectable	✓	✓	✓
Genomic instability (LOH/HRD)	✓	X	X
Tumour mutational burden (TMB)	✓	X	X
Microsatellite instability (MSI/MMR)	✓	X	X
Turnaround time	10–14 working days	7 working days	7 working days
Specimen type	Tumour tissue	Tumour tissue or liquid biopsy	Tumour tissue or liquid biopsy
Mnemonic	OCAPLUS	OPANGS	EGFRRASSEQ
Billing codes	4763 x 1 4765 x 24	4763 x 1 4765 x 10	4763 x 1 4765 x 4

For more information, contact 012 678 0645 or email ngs@ampath.co.za.